Immunophotonics is pleased to announce that the United States Patent and Trademark has issued U.S. Patent No. 11111316, which covers the composition of matter of its proprietary synthetic biopolymer, IP-001. Immunophotonics is currently conducting clinical studies for the use of IP-001 to treat various metastatic cancer indications and is exploring other applications of the drug outside oncology, such as within the field of infectious diseases. For more information on the patent, please see our press release here.